Albuminuria post-liver transplant is a predictor of kidney disease progression and mortality.

Julie Anne Ting, Dilshani Induruwage, Eric M Yoshida, Miten Dhruve, Nadia Y Zalunardo
{"title":"Albuminuria post-liver transplant is a predictor of kidney disease progression and mortality.","authors":"Julie Anne Ting,&nbsp;Dilshani Induruwage,&nbsp;Eric M Yoshida,&nbsp;Miten Dhruve,&nbsp;Nadia Y Zalunardo","doi":"10.3138/canlivj-2022-0019","DOIUrl":null,"url":null,"abstract":"<p><p><b>BACKGROUND:</b> Albuminuria is a marker of chronic kidney disease (CKD) associated with an increased risk of end-stage kidney disease (ESKD) and mortality in the general population, but it is uncertain whether the same association exists in liver transplant (LT) recipients. This study examined the association between albuminuria and kidney failure and mortality in LT recipients.<b>METHODS:</b> Retrospective cohort study of 294 adults who received a LT between January 1, 1989, and December 31, 2011, in British Columbia, Canada. Cox multivariable regression was used to determine the association between ACR and a primary combined outcome of mortality, doubling of serum creatinine, or ESKD; and a secondary outcome of a decrease in estimated glomerular filtration rate (eGFR) ≥30%. <b>RESULTS:</b> At baseline, mean eGFR was 67 (SD 20.9) mL/min/1.73 m<sup>2</sup>, and 10% had severe albuminuria (ACR >30 mg/mmol). The primary outcome occurred in 20.4% (60) of patients and was associated with ACR >30 mg/mmol (HR 2.77, 95% CI 1.28-6.04; <i>P</i> = 0.01). A decline in eGFR ≥30% occurred in 21.8% (64) of patients, and was associated with ACR >30 mg/mmol (HR 4.77, 95% CI 2.31-9.86; <i>P</i> < 0.0001). <b>CONCLUSIONS:</b> Severe albuminuria (ACR >30 mg/mmol) was associated with an increased risk of loss of kidney function and mortality after LT. Prospective studies are needed to determine if specific interventions directed at reducing albuminuria can improve long-term outcomes in LT recipients.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"2-13"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997516/pdf/canlivj-2022-0019.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian liver journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3138/canlivj-2022-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

BACKGROUND: Albuminuria is a marker of chronic kidney disease (CKD) associated with an increased risk of end-stage kidney disease (ESKD) and mortality in the general population, but it is uncertain whether the same association exists in liver transplant (LT) recipients. This study examined the association between albuminuria and kidney failure and mortality in LT recipients.METHODS: Retrospective cohort study of 294 adults who received a LT between January 1, 1989, and December 31, 2011, in British Columbia, Canada. Cox multivariable regression was used to determine the association between ACR and a primary combined outcome of mortality, doubling of serum creatinine, or ESKD; and a secondary outcome of a decrease in estimated glomerular filtration rate (eGFR) ≥30%. RESULTS: At baseline, mean eGFR was 67 (SD 20.9) mL/min/1.73 m2, and 10% had severe albuminuria (ACR >30 mg/mmol). The primary outcome occurred in 20.4% (60) of patients and was associated with ACR >30 mg/mmol (HR 2.77, 95% CI 1.28-6.04; P = 0.01). A decline in eGFR ≥30% occurred in 21.8% (64) of patients, and was associated with ACR >30 mg/mmol (HR 4.77, 95% CI 2.31-9.86; P < 0.0001). CONCLUSIONS: Severe albuminuria (ACR >30 mg/mmol) was associated with an increased risk of loss of kidney function and mortality after LT. Prospective studies are needed to determine if specific interventions directed at reducing albuminuria can improve long-term outcomes in LT recipients.

肝移植后蛋白尿是肾脏疾病进展和死亡率的预测指标。
背景:蛋白尿是慢性肾脏疾病(CKD)的一个标志,与一般人群终末期肾脏疾病(ESKD)和死亡率增加相关,但在肝移植(LT)受者中是否存在同样的关联尚不确定。本研究探讨了肾移植受者蛋白尿、肾功能衰竭和死亡率之间的关系。方法:对1989年1月1日至2011年12月31日期间在加拿大不列颠哥伦比亚省接受过肝移植的294名成年人进行回顾性队列研究。使用Cox多变量回归来确定ACR与死亡率、血清肌酐加倍或ESKD等主要综合结局之间的关系;次要结局是肾小球滤过率(eGFR)降低≥30%。结果:基线时,平均eGFR为67 (SD 20.9) mL/min/1.73 m2, 10%有严重蛋白尿(ACR >30 mg/mmol)。20.4%(60)的患者出现主要结局,并与ACR >30 mg/mmol相关(HR 2.77, 95% CI 1.28-6.04;P = 0.01)。21.8%(64例)的患者eGFR下降≥30%,且与ACR >30 mg/mmol相关(HR 4.77, 95% CI 2.31-9.86;P < 0.0001)。结论:重度蛋白尿(ACR >30 mg/mmol)与肝移植后肾功能丧失和死亡风险增加相关。需要前瞻性研究来确定针对减少蛋白尿的特定干预措施是否可以改善肝移植受者的长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信